155 related articles for article (PubMed ID: 38363480)
1. Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.
Nakamura T; Oya S; Ozawa H; Maehiro Y; Muta S; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Naito Y; Nagafuji K
Int J Hematol; 2024 Apr; 119(4):426-431. PubMed ID: 38363480
[TBL] [Abstract][Full Text] [Related]
2. The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia.
Watanabe S; Miyake K; Ogawa C; Matsumoto H; Yoshida K; Hirabayashi S; Hasegawa D; Inoue T; Kizu J; Machida R; Ohara A; Hosoya R; Manabe A
Int J Hematol; 2009 Oct; 90(3):347-352. PubMed ID: 19768519
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of ammonia concentration as a diagnostic test in monitoring of the treatment with L-asparaginase in children with acute lymphoblastic leukemia.
Czogała M; Balwierz W; Sztefko K; Rogatko I
Biomed Res Int; 2014; 2014():945860. PubMed ID: 25157375
[TBL] [Abstract][Full Text] [Related]
4. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
[TBL] [Abstract][Full Text] [Related]
5. Plasma ammonia concentration after L-asparaginase therapy in 27 dogs with high-grade lymphoma or leukemia.
Speas AL; Lyles SE; Wirth KA; Fahey CE; Kow K; Lejeune AT; Milner RJ
J Vet Emerg Crit Care (San Antonio); 2018 Mar; 28(2):130-139. PubMed ID: 29469204
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Kim HJ; Ock CY; Kim TM; Lee SH; Lee JY; Jung SH; Cho YS; Kim M; Keam B; Kim DW; Kim IH; Heo DS
Cancer Res Treat; 2018 Jul; 50(3):670-680. PubMed ID: 28675023
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Lee JH; Lee J; Yhim HY; Oh D; Bang SM
J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of L-asparaginase induced elevation of blood ammonia and hepatic encephalopathy].
Li Y; Ren HY; Cen XN; Yin Y; Liang ZY
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):578-80. PubMed ID: 23906449
[TBL] [Abstract][Full Text] [Related]
9. [The role of anti L-asparaginase antibody in childhood acute lymphoblastic leukemia].
Akazai A; Oda M; Nishiuchi R; Horiuchi T; Henmi M; Manki A; Seino Y
Rinsho Ketsueki; 1996 Feb; 37(2):95-100. PubMed ID: 8852025
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of treatment with L-asparaginase in children with acute lymphoblastic leukaemia, with a focus on silent inactivation and its influence on the treatment outcome.
Czogala M; Rogatko I; Pawińska-Wąsikowska K; Czogała W; Bal W; Ciebiera M; Chaber R; Chodała-Grzywacz A; Karolczyk G; Sztefko K; Balwierz W; Skoczeń S
Contemp Oncol (Pozn); 2022; 26(4):282-288. PubMed ID: 36816392
[TBL] [Abstract][Full Text] [Related]
11. L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.
Mohamed SA; Elshal MF; Kumosani TA; Aldahlawi AM; Basbrain TA; Alshehri FA; Choudhry H
Int J Environ Res Public Health; 2016 Oct; 13(10):. PubMed ID: 27754445
[No Abstract] [Full Text] [Related]
12. Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.
Walenciak J; Wyka K; Janczar S; Młynarski W; Zalewska-Szewczyk B
Pharmacol Rep; 2019 Apr; 71(2):311-318. PubMed ID: 30826572
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs: A multi-phase preclinical study.
Feenstra LR; Gehring R; van Geijswijk IM; König T; Prinsen HCMT; Vandemeulebroecke K; Lammens T; Krupa A; Teske E
Vet J; 2022 Aug; 286():105854. PubMed ID: 35781075
[TBL] [Abstract][Full Text] [Related]
14. L-Asparaginase delivery systems targeted to minimize its side-effects.
Talluri VP; Mutaliyeva B; Sharipova A; Ulaganathan V; Lanka SS; Aidarova S; Suigenbayeva A; Tleuova A
Adv Colloid Interface Sci; 2023 Jun; 316():102915. PubMed ID: 37159987
[TBL] [Abstract][Full Text] [Related]
15. Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients.
Wu J; Chen C; Huang S; Shen S; Chen J; Zhang S
Technol Cancer Res Treat; 2020; 19():1533033820980113. PubMed ID: 33287663
[TBL] [Abstract][Full Text] [Related]
16. Expression of asparagine synthetase predicts in vitro response to L-asparaginase in canine lymphoid cell lines.
Smallwood TL; Small GW; Suter SE; Richards KL
Leuk Lymphoma; 2014 Jun; 55(6):1357-65. PubMed ID: 24033105
[TBL] [Abstract][Full Text] [Related]
17. Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma.
Li Y; Zhang X; Hu T; Han L; Li R; Wen J; Zhang M
Oncol Rep; 2014 Aug; 32(2):853-9. PubMed ID: 24913732
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
[TBL] [Abstract][Full Text] [Related]
20. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
